These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10660387)

  • 21. Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation.
    Torp-Pedersen C; Brendorp B; Køber L
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2695-704. PubMed ID: 11060831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter.
    Lindeboom JE; Kingma JH; Crijns HJ; Dunselman PH
    Am J Cardiol; 2000 Apr; 85(8):1031-3. PubMed ID: 10760352
    [No Abstract]   [Full Text] [Related]  

  • 23. Incidence of atrial fibrillation in patients with either heart failure or acute myocardial infarction and left ventricular dysfunction: a cohort study.
    Schmiegelow MD; Pedersen OD; Køber L; Seibæk M; Abildstrøm SZ; Torp-Pedersen C
    BMC Cardiovasc Disord; 2011 May; 11():19. PubMed ID: 21569543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group.
    Frost L; Mortensen PE; Tingleff J; Platou ES; Christiansen EH; Christiansen N
    Int J Cardiol; 1997 Jan; 58(2):135-40. PubMed ID: 9049678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dofetilide (Tikosyn): a new drug to control atrial fibrillation.
    Saliba WI
    Cleve Clin J Med; 2001 Apr; 68(4):353-63. PubMed ID: 11326815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase IV trial evaluating the effectiveness and safety of dofetilide.
    Guanzon AV; Crouch MA
    Ann Pharmacother; 2004; 38(7-8):1142-7. PubMed ID: 15161945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. QTC intervals can be assessed with the AliveCor heart monitor in patients on dofetilide for atrial fibrillation.
    Chung EH; Guise KD
    J Electrocardiol; 2015; 48(1):8-9. PubMed ID: 25453194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) study.
    Pedersen OD; Brendorp B; Elming H; Pehrson S; Køber L; Torp-Pedersen C
    Card Electrophysiol Rev; 2003 Sep; 7(3):220-4. PubMed ID: 14739717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter.
    Suttorp MJ; Polak PE; van 't Hof A; Rasmussen HS; Dunselman PH; Kingma JH
    Am J Cardiol; 1992 Feb; 69(4):417-9. PubMed ID: 1734660
    [No Abstract]   [Full Text] [Related]  

  • 30. Practical approach to the use and monitoring of dofetilide therapy.
    Tran A; Vichiendilokkul A; Racine E; Milad A
    Am J Health Syst Pharm; 2001 Nov; 58(21):2050-9. PubMed ID: 11715827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dofetilide: a new pure class III antiarrhythmic agent.
    Falk RH; Decara JM
    Am Heart J; 2000 Nov; 140(5):697-706. PubMed ID: 11054613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dofetilide for the prevention of postoperative atrial fibrillation after coronary surgery: is it a useful routine prophylaxis?
    Mariscalco G; Sala A; Banach M; Cattaneo P
    Am J Cardiol; 2008 Aug; 102(4):506. PubMed ID: 18678316
    [No Abstract]   [Full Text] [Related]  

  • 33. Frequency of toxicity with chemical conversion of atrial fibrillation with dofetilide.
    Brumberg G; Gera N; Pray C; Adelstein E; Barrington W; Bazaz R; Mendenhall GS; Nemec J; Voigt A; Wang NC; Schwartzman D; Saba S; Jain SK
    Am J Cardiol; 2013 Aug; 112(4):505-8. PubMed ID: 23706388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Practice variation in the re-initiation of dofetilide: An observational study.
    Turagam MK; Afzal MR; Reddy M; Pillarisetti J; Lavu M; Atkins D; Jeffrey C; Christensen K; Pimentel R; Dendi R; Vacek J; Hurwitz J; Di Biase L; Natale A; Lakkireddy D
    Int J Cardiol; 2017 Jun; 236():221-225. PubMed ID: 28233630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dofetilide: is the treatment worse than the disease?
    Lauer MR
    J Am Coll Cardiol; 2001 Mar; 37(4):1106-10. PubMed ID: 11263616
    [No Abstract]   [Full Text] [Related]  

  • 36. DIAMOND antiarrhythmic trials. Danish Investigations of Arrhythmia and Mortality on Dofetilide.
    Møller M
    Lancet; 1996 Dec; 348(9041):1597-8. PubMed ID: 8950921
    [No Abstract]   [Full Text] [Related]  

  • 37. Ibutilide (Corvert): suspected association with torsades de pointes.
    CMAJ; 2004 Oct; 171(8):994. PubMed ID: 15497210
    [No Abstract]   [Full Text] [Related]  

  • 38. Management of heart failure.
    Le Jemtel TH
    Curr Cardiol Rep; 2000 May; 2(3):221-4. PubMed ID: 10980896
    [No Abstract]   [Full Text] [Related]  

  • 39. Dofetilide-Induced Severe Hepatotoxicity.
    Subedi R; Dean RK; Dhamoon AS
    Am J Ther; 2018; 25(6):e783-e784. PubMed ID: 29912716
    [No Abstract]   [Full Text] [Related]  

  • 40. New antiarrhythmic agents for atrial fibrillation.
    Conway DS; Lip GY
    Curr Opin Investig Drugs; 2001 Jan; 2(1):87-92. PubMed ID: 11527018
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.